OncoMatch

OncoMatch/Clinical Trials/NCT07069699

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Is NCT07069699 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Pidnarulex for burkitt lymphoma.

Phase 1/2RecruitingNational Cancer Institute (NCI)NCT07069699Data as of May 2026

Treatment: PidnarulexThis phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: BCL2 rearrangement

Required: BCL6 rearrangement

Required: MYC rearrangement

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 2 prior lines

Lab requirements

Blood counts

Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL

Kidney function

GFR ≥ 60 mL/min, calculated by eGFR × BSA / 1.73 m^2

Liver function

Total bilirubin ≤ 1.5 institutional ULN (≤ 3 × ULN if Gilbert's syndrome and direct bilirubin normal); AST/ALT ≤ 3 × ULN

Cardiac function

NYHA class II or better; baseline QTc ≤ 480 msec

Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL; Total bilirubin ≤ 1.5 institutional ULN (≤ 3 × ULN if Gilbert's syndrome and direct bilirubin normal); AST/ALT ≤ 3 × ULN; GFR ≥ 60 mL/min, calculated by eGFR × BSA / 1.73 m^2; NYHA class II or better; baseline QTc ≤ 480 msec

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Yale University Cancer Center LAO · New Haven, Connecticut
  • University of Oklahoma Health Sciences Center · Oklahoma City, Oklahoma

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify